AI Article Synopsis

  • A Drosophila nucleotide sugar transporter was identified as a homologue to the human UDP-Gal transporter, indicating evolutionary similarities in sugar transport processes.
  • When tested in mammalian cells, the Drosophila transporter successfully compensated for specific transport deficiencies, revealing its functionality in a different cellular context.
  • Mutations in conserved amino acids impacted the protein's stability and distribution, showing that structural integrity is crucial for the transporter's proper function and substrate recognition.

Article Abstract

A putative Drosophila nucleotide sugar transporter was characterized and shown to be the Drosophila homologue of the human UDP-Gal transporter (hUGT). When the Drosophila melanogaster UDP-Gal transporter (DmUGT) was expressed in mammalian cells, the transporter protein was localized in the Golgi membranes and complemented the UDP-Gal transport deficiency of Lec8 cells but not the CMP-Sia transport deficiency of Lec2 cells. DmUGT and hUGT were expressed in Saccharomyces cerevisiae cells in functionally active forms. Using microsomal vesicles isolated from Saccharomyces cerevisiae expressing these transporters, we unexpectedly found that both hUGT and DmUGT could transport UDP-GalNAc as well as UDP-Gal. When amino-acid residues that are conserved among human, murine, fission yeast and Drosophila UGTs, but are distinct from corresponding ones conserved among CMP-Sia transporters (CSTs), were substituted by those found in CST, the mutant transporters were still active in transporting UDP-Gal. One of these mutants in which Asn47 was substituted by Ala showed aberrant intracellular distribution with concomitant destabilization of the protein product. However, this mutation was suppressed by an Ile51 to Thr second-site mutation. Both residues were localized within the first transmembrane helix, suggesting that the structure of the helix contributes to the stabilization and substrate recognition of the UGT molecule.

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.0014-2956.2001.02632.xDOI Listing

Publication Analysis

Top Keywords

udp-gal transporter
8
transport deficiency
8
saccharomyces cerevisiae
8
udp-gal
5
human drosophila
4
drosophila udp-galactose
4
transporters
4
udp-galactose transporters
4
transport
4
transporters transport
4

Similar Publications

Article Synopsis
  • Glycosylation significantly influences the pharmacological properties of biologics, leading to variability in their glycan structures and posing challenges for consistent therapeutic development.
  • The study uses omics technologies, specifically RNA-sequencing, to predict optimal cell lines for producing specific glycosylation profiles in monoclonal antibodies (mAbs), identifying Alg5 and UDP-Gal transporter levels as key predictive markers.
  • While transcriptomic data is useful in forecasting glycosylation trends, it fails to capture important factors like enzyme localization and cellular dynamics that are crucial for the actual outcomes of glycosylation.
View Article and Find Full Text PDF

Slc35a2 mosaic knockout impacts cortical development, dendritic arborisation, and neuronal firing.

Neurobiol Dis

October 2024

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC 3052, Australia; Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC 3084, Australia. Electronic address:

Mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is an important cause of drug-resistant epilepsy. A significant subset of individuals diagnosed with MOGHE display somatic mosaicism for loss-of-function variants in SLC35A2, which encodes the UDP-galactose transporter. We developed a mouse model to investigate how disruption of this transporter leads to a malformation of cortical development.

View Article and Find Full Text PDF

Loss of Slc35a2 alters development of the mouse cerebral cortex.

Neurosci Lett

July 2024

Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH, United States; Dept. of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, United States. Electronic address:

Brain somatic variants in SLC35A2, an intracellular UDP-galactose transporter, are commonly identified mutations associated with drug-resistant neocortical epilepsy and developmental brain malformations, including focal cortical dysplasia type I and mild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE). However, the causal effects of altered SLC35A2 function on cortical development remain untested. We hypothesized that focal Slc35a2 knockout (KO) or knockdown (KD) in the developing mouse cortex would disrupt cortical development and change network excitability.

View Article and Find Full Text PDF

Background: Solute carrier family 35 member A2 (SLC35A2), which belongs to the SLC35 solute carrier family of human nucleoside sugar transporters, has shown regulatory roles in various tumors and neoplasms. However, the function of SLC35A2 across human cancers remains to be systematically assessed. Insights into the prediction ability of SLC35A2 in clinical practice and immunotherapy response remains limited.

View Article and Find Full Text PDF

Nucleotide sugar transporter SLC35A2 is involved in promoting hepatocellular carcinoma metastasis by regulating cellular glycosylation.

Cell Oncol (Dordr)

April 2023

Liver Cancer Institute, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Zhongshan Hospital, Building19, No. 180, Fenglin Road, 20032, Shanghai, People's Republic of China.

Purpose: Recently, aberrant glycosylation has been recognized to be relate to malignant behaviors of cancer and outcomes of patients with various cancers. SLC35A2 plays an indispensable role on glycosylation as a nucleotide sugar transporter. However, effects of SLC35A2 on malignant behaviors of cancer cells and alteration of cancer cells surface glycosylation profiles are still not fully understood, particularly in hepatocellular carcinoma (HCC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!